Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Arecor Therapeutics PLC ( (GB:AREC) ) just unveiled an announcement.
Arecor Therapeutics plc announced the grant of 230,000 options to its Chief Financial Officer, David Ellam, under the company’s Long Term Incentive Plan and All Employee Share Ownership Plan. This move is part of Arecor’s strategy to incentivize and retain key management personnel, potentially impacting the company’s operational focus and aligning management interests with shareholder value.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a globally focused biopharmaceutical company that enhances existing therapeutic products to transform patient care. Utilizing its proprietary Arestat™ technology platform, Arecor develops a portfolio of proprietary products in diabetes and other indications, collaborating with leading pharmaceutical and biotechnology companies.
YTD Price Performance: -48.30%
Average Trading Volume: 17,913
Technical Sentiment Signal: Buy
Current Market Cap: £14.35M
For a thorough assessment of AREC stock, go to TipRanks’ Stock Analysis page.